secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bionano Genomics, Inc. (BNGO)
CIK:        0001411690
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001140361-26-000904
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bionano reports preliminary Q4/FY 2025 revenue down 2-8% YoY; cash $29.6M
-------------------------------------------------------------------------

- Total Q4 revenue $7.8-8.0M, down 2-4% YoY; full-year $28.4-28.6M, down 7-8%.
- Installed 9 new OGM systems in Q4, 32 in FY; installed base at 387 systems at year-end.
- Cash, equivalents and restricted investments $29.6M as of Dec 31, 2025 ($10.3M restricted).
- Nanochannel array flowcells sold: 7,554 in Q4, 30,171 for full year 2025.
- Preliminary unaudited results; subject to change after year-end close and audit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411690/000114036126000904/0001140361-26-000904-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411690/000114036126000904/ef20062688_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-000904

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer